Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases

Tyler Patchen

News Reporter

The Italian drug developer Chiesi will be looking to drop nine figures to develop several treatments for respiratory diseases in a deal with Swedish biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

ADCs from a decade-old Singapore biotech find new life with $187M

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Chiesi puts down $200M+ to col­lab­o­rate with Af­fi­body for res­pi­ra­to­ry dis­eases

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Chiesi puts down $200M+ to collaborate with Affibody for respiratory diseases